Navigator Medicines, Inc.
Undisclosed of $10.0M

Undisclosed of $10.0M
Undisclosed of $10.0M
Undisclosed of $50.0M
Undisclosed of $56.3M
Undisclosed of $8.5M
Undisclosed of $7.8M
FDA goal date for relutrigine (NDA), for SCN2A and SCN8A developmental and epileptic encephalopathies
FDA goal date for zilurgisertib (NDA), for fibrodysplasia ossificans progressiva
FDA goal date for zilganersen
Change in directors or officers
Change in directors or officers
Change in directors or officers
Change in directors or officers
Change in directors or officers